Ways to improve the effectiveness of glaucoma filtering surgery
https://doi.org/10.21516/2072-0076-2024-17-2-99-107
Abstract
The article presents a variety of ways to increase the efficiency of glaucoma filtering surgery. Special attention is given to maintaining the ocular surface healthy through optimal glaucoma therapy. The duration of the disease should be taken into account when choosing the type of hypotensive surgery and designing an algorithm for its pharmacological support: preoperative preparation, prolonged postoperative anti-inflammatory treatment and cornea protection.
About the Authors
V. P. Nikolaenko
St. Petersburg State University;
City Multidisciplinary Hospital No. 2
Russian Federation
Russian Federation
Vadim P. Nikolaenko — Dr. of Med. Sci., professor, department of otorhinolaryngology and ophthalmology; deputy chief physician for ophthalmology
7/9, Universitetskaya Emb., St. Petersburg, 199106;
5, Uchebny Lane, St. Petersburg, 194354
A. V. Antonova
St. Petersburg State University;
City Multidisciplinary Hospital No. 2
Russian Federation
Russian Federation
Anastasiya V. Antonova — assistant of chair of otorhinolaryngology and ophthalmology; ophthalmologist
7/9, Universitetskaya Emb., St. Petersburg, 199106;
5, Uchebny Lane, St. Petersburg, 194354
V. V. Brzhesky
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Vladimir V. Brzhesky — Dr. of Med. Sci., head of chair of ophthalmology
2, Litovskaya St., St. Petersburg, 194100
References
1. European Glaucoma Society Terminology and Guidelines for Glaucoma, 5; Savona. PubliComm; 2020.
2. Primary open angle glaucoma. Clinical Guidelines. Moscow; 2020 (In Russ.).
3. Gedde SJ, Vinod K, Wright MM, et al. American Academy of Ophthalmology preferred practice pattern glaucoma panel. Primary open-angle glaucoma preferred practice pattern. Jan 2020; 128 (1): 71–150. doi: 10.1016/j.ophtha.2020.10.022
4. Tanna AP. Basic and clinical science course. Section 10. Glaucoma. American Academy of Ophthalmology. San Francisco: AAO, 2022–2023.
5. Weinreb RN, Ramulu P, Topouzis F, et al. 11th Consensus Meeting: Glaucoma Surgery. World Glaucoma Association, 2019.
6. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999; 106 (3): 556–63. doi: 10.1016/S0161-6420(99)90116-1
7. Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004; 111 (1): 45–52. doi: 10.1016/j.ophtha.2003.03.001
8. Asbell PA, Potapova N. Effects of topical antiglaucoma medications on the ocular surface. Ocular Surface. 2005; 3 (1): 27–40. doi: 10.1016/s1542-0124(12)70120-9
9. Hong S, Lee CS, Seo KY, Seong GJ, Hong Y J. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol. 2006 Jul; 142 (1): 185–6. doi: 10.1016/j.ajo.2006.02.056
10. Servat JJ, Bernardino CR. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging. 2011 Apr 1; 28 (4): 267–82. doi: 10.2165/11588830-000000000-00000
11. Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990; 108 (11): 1543–8. doi: 10.1001/archopht. 1990.01070130045027
12. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication II. The outcome of filtration surgery. Arch Ophthalmol. 1994; 112 (11): 1446–54. doi: 10.1001/archopht.1994.01090230060021
13. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication I. The conjunctival cell profile. Arch Ophthalmol. 1994; 112 (11): 1437–45. doi: 10.1001/archopht.1994.01090230051020
14. Helin M, Rönkkö S, Puustjärvi T, et al. Conjunctival inflammatory cells and their predictive role for deep sclerectomy in primary open-angle glaucoma and exfoliation glaucoma. J Glaucoma. 2011; 20 (3): 172–8. doi: 10.1097/IJG.0b013e3181d9ccb0
15. Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: The PESO study. J Glaucoma. 2013; 22 (9): 730–5. doi: 10.1097/IJG.0b013e31825af67d
16. Helin-Toiviainen M, Rönkkö S, Puustjärvi T, et al. Conjunctival matrix metalloproteinases and their inhibitors in glaucoma patients. Acta ophthalmologica. 2015 Mar; 93 (2): 165–71. doi: 10.1111/aos.12550
17. Aritüгk N, Oge I, Baris S, et al. The effects of antiglaucomatous agents on conjunctiva used for various durations. Int. Ophthalmol. 1996–1997; 20 (1–3): 57–62. doi: 10.1007/BF00212947
18. Antonova A.V., Nikolaenko V.P., Brzheskiy V.V., Vuks A.Ja. Factors influencing the effectiveness of trabeculectomy: following materials of the City Multidisciplinary Hospital No. 2. Ophthalmology Reports. 2022; 15 (4): 35–44 (In Russ.). doi: 10.17816/OV159363
19. Agnifili L, Mastropasqua R, Fasanella V, et al. Gland features and conjunctival goblet cell density in glaucomatous patients controlled with prostaglandin/timolol fixed combinations: A case control, cross-sectional study. J Glaucoma. 2018; 27 (4): 364–70. doi: 10.1097/IJG. 0000000000000899
20. Mastropasqua L, Agnifili L, Fasanella V, et al. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study. Acta Ophthalmol. 2013; 91 (5): e397-405. doi: 10.1111/aos.12131
21. Russ HH, Costa VP, Ferreira FM, et al. Conjunctival changes induced by prostaglandin analogues and timolol maleate: a histomorphometric study. Arq Bras Oftalmol. 2007; 70 (6): 910–6. doi: 10.1590/s0004-27492007000600005
22. Rodríguez Uña I, Martínez-de-la-Casa JM, Pablo Júlvez L, et al. Perioperative pharmacological management in patients with glaucoma. Arch Soc Esp Oftalmol. 2015; 90 (6): 274–84. doi: 10.1016/j.oftal.2014.06.003
23. Guenoun JM, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005; 46 (7): 2444–50. doi: 10.1167/iovs.04-1331
24. Kim EJ, Kim YH, Kang SH, Lee KW, Park YJ. In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells. Korean J Ophthalmol. 2013; 27 (6): 446–53. doi: 10.3341/kjo.2013.27.6.446
25. Oblovatskaya E.S., Nikolaenko V.P. Ahmed valve implant and its place in the surgical treatment of glaucoma. National journal glaucoma. 2022; 21 (2): 35–41 (In Russ.). doi: 10.53432/2078-4104-2022-21-2-35-41
26. Lichter PR, Musch DC, Gillespie BW, et al. CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001; 108 (11): 1943–53. doi: 10.1016/s0161-6420(01)00873-9
27. Richter CU, Shingleton, BJ, Bellows AR, et al. The development encapsulated filtering blebs. Ophthalmology. 1988 Sep; 95 (9): 1163–8. doi: 10.1016/s0161-6420(88)33041-1
28. Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol. 2012; 6: 441–6. doi: 10.2147/OPTH. S29158
29. Antonova A.V., Nikolaenko V.P., Brzhesky V.V., Vuks A.Ya. The efficacy of sinustrabeculectomy in the modern clinical practice. Clinical Ophthalmology. 2023; 23 (1): 21–6 (in Russ.). doi: 10.32364/2311-7729-2023-23-1-21-26
30. Shaarawy T, Sherwood MB., Crowston JG. Glaucoma: Medical diagnosis & therapy. Elsevier Health Sciences, 2009.
31. Tailor R, Batra R, Mohamed S. A national survey of glaucoma specialists on the preoperative (trabeculectomy) management of the ocular surface. Semin. Ophthalmol. 2016; 31 (6): 519–25. doi: 10.3109/08820538.2014.986585
32. Chamard C, Larrieu S, Baudouin C, et al. Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008–2016. Acta Ophthalmol. 2020; 98 (7):e876-e881. doi: 10.1111/aos.14410
33. Safonova T.N., Fedorov A.A., Zabegaylo A.O., Egorova G.B., Mitichkina T.S. Treatment of dry eye syndrome by primary glaucoma. National journal Glaucoma. 2015; 14 (4): 36–43 (In Russ.).
34. Egorova G.B., Averich V.V. Reducing cytotoxic action of the preservative employed in ophthalmic hypotensive medications with tear replacement therapy. Vestnik oftal’mologii. 2018; 134 (3): 48–56 (In Russ.). doi: 10.17116/oftalma 2018134348
35. Makashova N.V., Vasil'eva A.E., Kolosova O.Yu. Effects of artificial tears on ocular surface in glaucomatous patients with long-term instillation of preserved antiglaucoma eye drops. Vestnik oftal’mologii. 2018; 134 (2): 59–65 (In Russ.). doi 10.17116/oftalma2018134259-65
36. Nguyen KD, Lee DA. Effect of steroids and nonsteroidal antiinflammatory agents on human ocular fibroblast. Invest Ophthalmol Vis Sci. 1992 Aug; 33 (9): 2693–701. PMID: 1386351.
37. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008; 4 (10): 525–33. https://doi.org/10.1038/ncprheum0898
38. Löwenberg M, Stahn C, Hommes DW, Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids. 2008; 73 (9–10): 1025–9. doi: 10.1016/j.steroids.2007.12.002
39. Stewart RH, Smith JP, Rosenthal AL. Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate. Curr Eye Res. 1984; 3 (6): 835–9. doi: 10.3109/02713688409000796
40. Petrov S.Yu., Antonov A.A., Makarova А.S., Vostrukhin S.V., Safonova D.М. Options for prolonging the hypotensive effect of trabeculectomy. Vestnik otal’mologii. 2015; 131 (1): 75–81 (in Russ.). doi: 10.17116/oftalma2015131175-81
41. Broadway DC, Grierson I, Stürmer J, Hitchings RA. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch Ophthalmol. 1996; 114 (3): 262–7. doi: 10.1001/archopht.1996.01100130258004
42. Mastropasqua L, Brescia L, D’Arcangelo F, et al. Topical steroids and glaucoma filtration surgery outcomes: an in vivo confocal study of the conjunctiva. J Clin Med. 2022; 11 (14): 3959. doi: 10.3390/ jcm11143959
43. Taniguchi J, Sharma A. Fluorometholone modulates gene expression of ocular surface mucins. Acta Ophthalmol. 2019; 97 (8): e1082-e1088. doi: 10.1111/aos.14113
44. Aleksandrova O.I., Okolov I.N., Khorolskaya Yu.I., Panovа I.E., Blinova M.I. Influence of non-steroid antiinflammatory eye drops on the epithelium cells of the cornea and conjunctiva in vitro. Ophthalmology in Russia. 2017; 15 (3): 251–9 (In Russ.). doi: 10.18008/1816-5095-2017-3-251-259
45. Nikolaenko V.P., Brzheskiy V.V., Antonova А.V. The extension of indications for the implantation of Ahmed valve. Ophthalmology reports. 2023; 16 (2): 83–90 (In Russ.). doi: 10.17816/OV340821
46. Pérez-Bartolomé F, Martínez-de-la-Casa JM, Arriola-Villalobos P, et al. Ocular surface disease in patients under topical treatment for glaucoma. Eur J Ophthalmol. 2017; 27 (6): 694–704. doi: 10.5301/ejo.5000977
47. Antonova A.V., Nikolaenko V.P., Brzheskiy V.V. Realization of a cascade treatment algorithm for glaucoma in St. Petersburg. Russian journal of clinical ophthalmology. 2021; 21 (3): 123–8 (In Russ.). doi: 10.32364/2311-7729-2021-21-3-123-128
48. Antonova A.V., Nikolaenko V.P., Brzeskii V.V., Vuks A.Ja., Koskin S.A. The influence of some general diseases for changes on the ocular surface after trabeculectomy. Ophthalmology reports. 2024; 17 (1): 7–19 (In Russ.). doi:10.17816/OV568993
49. Husain R, Liang S, Foster PJ, et al. Cataract surgery after trabeculectomy: the effect on trabeculectomy function. Arch Ophthalmol. 2012; 130 (2): 165–70. doi: 10.1001/archophthalmol.2011.329
50. Klink J, Schmitz B, Lieb WE, et al. Filtering bleb function after clear cornea phacoemulsification: a prospective study. Br J Ophthalmol. 2005; 89 (5): 597–601. doi: 10.1136/bjo.2004.041988
51. Ehrnrooth P, Lehto I, Puska P, Laatikainen L. Phacoemulsification in trabeculectomized eyes. Acta Ophthalmol Scand. 2005 Oct; 83 (5): 561–6. doi: 10.1111/j.1600-0420.2005.00499.x
52. Crichton ACS, Kirker AW. Intraocular pressure and medication control after clear corneal phacoemulsification and AcrySof posterior chamber intraocular lens implantation in patients with filtering blebs. J Glaucoma. 2001 Feb; 10 (1): 38–46. doi: 10.1097/00061198-200102000-00008
53. Halikiopoulos D, Moster MR, Azuara-Blanco A, et al. The outcome of the functioning filter after subsequent cataract extraction. Ophthalmic Surg Lasers. 2001 Mar-Apr; 32 (2): 108–17. PMID: 11300631
54. Aptel F, Colin C, Kaderli S, et al. Management of postoperative inflammation after cataract and complex ocular surgeries: a systematic review and Delphi survey. Br J Ophthalmol. 2017; 101 (11): 1–10. doi: 10.1136/bjophthalmol-2017-310324
55. Khaw PT, Bouremel Y, Brocchini S, et al. The control of conjunctival fibrosis as a paradigm for the prevention of ocular fibrosis-related blindness. “Fibrosis has many friends”. Eye (Lond). 2020; 34 (12): 2163–74. doi: 10.1038/s41433-020-1031-9
56. Egorov E.A., Kuroyedov A.V., eds. Primary open-angle glaucoma. National Guidelines. Moscow: GEOTAR-Media, 2023 (In Russ.).
Review
For citations:
Nikolaenko V.P., Antonova A.V., Brzhesky V.V. Ways to improve the effectiveness of glaucoma filtering surgery. Russian Ophthalmological Journal. 2024;17(2):99-107. (In Russ.) https://doi.org/10.21516/2072-0076-2024-17-2-99-107
Views:
508
Email this article 